Results 131 to 140 of about 74,736 (296)

The Alpha‐1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Alpha‐1 antitrypsin deficiency is a genetic disease that affects the lungs and the liver. The role of the heterozygous genetic defect in the development of liver cancer in patients with cirrhosis is unclear. Our study found that carrying the Pi*MZ genotype increases the risk of developing liver cancer.
Lorenz Balcar   +18 more
wiley   +1 more source

Effects of serum-clot contact time on second-trimester prenatal screening markers and their stability in serum [PDF]

open access: yesJournal of Medical Biochemistry, 2010
Alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol are screening markers for fetal trisomies and structural disorders of the neural tube defect type.
Bujišić Nada
doaj  

Reproductive tract biology: Of mice and men. [PDF]

open access: yes, 2019
The study of male and female reproductive tract development requires expertise in two separate disciplines, developmental biology and endocrinology.
Baskin, Laurence S   +5 more
core  

Guideline of guidelines: management of small testicular masses

open access: yesBJU International, EarlyView.
Objective To compare and summarise the most up to date international guidelines and major recommendations for the management of small testicular masses (STMs). Methods A systematic search was conducted in PubMed, EMBASE, Scopus, Google Scholar, and the Cochrane Library up to 1 November 2024.
Marco Tozzi   +7 more
wiley   +1 more source

Targeting SPP1‐CD44‐Hedgehog Axis Elicits Therapeutic Effects in Hepatocellular Carcinoma by Suppressing Intratumoral Fibrosis

open access: yesCancer Science, EarlyView.
SPP1 was identified as a key driver of intratumoral fibrosis and hepatocellular carcinoma (HCC) progression through transcriptomic, histological, and functional analyses. Mechanistically, SPP1 promotes HSC activation and fibrosis via the SPP1–CD44–GLI1 axis, and pharmacologic inhibition of Hedgehog signaling effectively reduces tumor growth and ...
Atsushi Nara   +16 more
wiley   +1 more source

A Closer Look at the Global Management of Spina Bifida: The Implementation of Endoscopic Third Ventriculostomy in the Treatment of Spina Bifida-Related Hydrocephalus in Africa [PDF]

open access: yes, 2018
Spina bifida, specifically myelomeningocele, is a debilitating neural tube defect that affects patients and families throughout the world. Traditional management and treatment methods are described, followed by an explanation of why this is often ...
Burckart, Caryssa
core   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

open access: yesHepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya   +13 more
wiley   +1 more source

The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization [PDF]

open access: gold, 2016
Lei Liu   +15 more
openalex   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

open access: yesHepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy